RNAi-Loaded Nanocarriers Targeting the IL-6/JAK-STAT3-NF-κB Cytokine Axis in Rheumatoid Arthritis
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation, progressive cartilage degradation, and bone erosion driven by complex cytokine-mediated signaling networks. Central to its pathogenesis is the dysregulated interplay of the interleukin-6 (IL-6)/Janus kinase (JAK)-signal transducer and activator of transcription-3 (STAT3) and nuclear factor kappa-B (NF-κB) pathways, which coordinate transcription of pro-inflammatory cytokines, angiogenic mediators, and osteoclastogenic factors. Conventional therapeutic strategies, including biologics and small-molecule inhibitors, primarily target extracellular mediators and often fail to adequately suppress intracellular signaling redundancy, leading to incomplete or transient clinical responses. RNA interference (RNAi) has emerged as a promising gene-silencing approach capable of selectively downregulating disease-driving transcripts at the post-transcriptional level. However, the clinical translation of RNAi is limited by instability, poor cellular uptake, and rapid degradation of naked small interfering RNA (siRNA). Nanocarrier-based delivery systems provide a transformative solution by protecting siRNA, enhancing pharmacokinetics, enabling targeted delivery to pathogenic cells, and facilitating cytoplasmic release through stimuli-responsive mechanisms. These RNAi-loaded nanoplatforms can simultaneously modulate multiple inflammatory nodes, reprogram immune-cell behavior, attenuate oxidative stress, and inhibit osteoclast genesis, thereby addressing RA as a systems-level disease. Furthermore, advances in precision targeting and multifunctional nanotechnology highlight the broader applicability of this strategy to other cytokine-driven disorders. Despite existing translational challenges, RNAi nanomedicine represents a paradigm shift toward network-oriented, gene-level therapeutics with the potential to achieve durable immunomodulation and disease modification in rheumatoid arthritis.
Keywords: Inflammation; JAK-STAT3 signaling; nanocarriers; NF-κB; RNA interference; rheumatoid arthritis
Keywords:
Inflammation, JAK-STAT3 signaling, nanocarriers, NF-κB; RNA interference, rheumatoid arthritisDOI
https://doi.org/10.22270/jddt.v16i3.7633References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2020;396(10266):1789-1801. doi:10.1016/S0140-6736(20)30173-8
2. Tanaka Y. Rheumatoid arthritis inflammation and JAK-STAT signaling pathway. Nat Rev Rheumatol. 2020;16(7):401-402. doi:10.1038/s41584-020-0445-7
3. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2021;72:11-25. doi:10.1146/annurev-med-042819-103450
4. Singh R, Prasad J, Satapathy T, Jain P, Singh S. Pharmacological evaluation for anti-bacterial and anti-inflammatory potential of polymeric microparticles. Indian Journal of Biochemistry and Biophysics (IJBB). 2021; 58(2):156-61. https://doi.org/10.56042/ijbb.v58i2.35105
5. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2021; 6:52. doi:10.1038/s41392-021-00513-4
6. Dwivedi C, Yadav R, Tiwari SP, Satapathy T, Roy A. Management of Rheumatoid Arthritis: An Overview. 2014;3(2): 3424-3442.
7. Bai L, Su P. Nanocarrier-based delivery of siRNA therapeutics in rheumatoid arthritis: immune mechanisms and translational perspectives. Front Immunol. 2025;16:1718256. doi:10.3389/fimmu.2025.1718256
8. Kumari A, Kaur A, Aggarwal G. The emerging potential of siRNA nanotherapeutics in treatment of arthritis. Asian J Pharm Sci. 2023;18(5):100845. doi:10.1016/j.ajps.2023.100845
9. Sahu S, Jain P, Deshmukh R, Samal PK, Satapathy T, Ajazuddin. Psoriatic arthritis in transition: cytokine signaling, immune dysregulation, and therapeutic innovation. Inflammopharmacology. 2025 Aug; 33(8):4275-90. https://doi.org/10.1007/s10787-025-01865-0
10. Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316-333. doi:10.1038/s41584-020-0413-2
11. Rose-John S. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. Nat Rev Immunol. 2021;21(6):448-463. doi:10.1038/s41577-021-00569-0
12. Sahu P, Satapathy T. Immunopharmacology of senescence: targeting the senescence-associated secretory phenotype (SASP) - a mechanism-based review. Inflammopharmacology. 2025 Aug; 33(8):4291-310. https://doi.org/10.1007/s10787-025-01867-y
13. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Front Immunol. 2022;13:910863. doi:10.3389/fimmu.2022.910863
14. Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2021;61:1-15. doi:10.1016/j.cytogfr.2021.06.001
15. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and the role of MAPK signaling. Int J Mol Sci. 2022;23(9):4892. doi:10.3390/ijms23094892
16. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2020; 19(6):421-446. doi:10.1038/s41573-020-0077-1
17. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid arthritis: from pathogenesis to clinical impact. Autoimmun Rev. 2021;20(4):102769. doi:10.1016/j.autrev.2021.102769
18. Rathi D, Tiwari K, Satapathy T. Janus Kinase Inhibitors (JAK) As Potential Candidate Targets to Rheumatoid Arthritis. Curr. Res. Altern. Complement. Integr. Med. 2025; 2:79-89.
19. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer and inflammatory diseases. Nat Rev Clin Oncol. 2021;18(4):234-248. doi:10.1038/s41571-020-00462-7
20. Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630-643. doi:10.1038/s41565-021-00898-0
21. Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2022; 13:268. doi:10.1038/s41467-021-27947-2
22. Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2023;41(1):21-31. doi:10.1038/s41587-022-01474-6
24. Satapathy T, Kaushik S, Netam AK, Prasad J, Rao SP, Sahu MK, Baghel P. Nano delivery: A smart carrier for treatment of ovarian cancer. World J. Pharm. Res. 2018 Mar 19; 7(9):513-23. DOI: 10.20959/wjpr20189-12137.
25. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020; 19(10):673-694. doi:10.1038/s41573-020-0075-3
26. Dowdy SF. Endosomal escape of RNA therapeutics: how do we solve this rate-limiting problem? Nat Biotechnol. 2023;41(1):21-31. doi:10.1038/s41587-022-01474-6
27. Yu AM, Choi YH, Tu MJ. RNA drugs and RNA targets for small molecules: principles, progress, and challenges. Pharmacol Rev. 2020;72(4):862-898. doi:10.1124/pr.120.019554
28. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi:10.1038/s41578-021-00358-0
29. Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630-643. doi:10.1038/s41565-021-00898-0
30. Riley MK, Vermerris W. Recent advances in nanomaterials for gene delivery—a review. Nanomaterials (Basel). 2021;11(7):1747. doi:10.3390/nano11071747
31. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-0090-8
32. Li Z, Jiang H, Xu C, Gu L. A review: using nanoparticles to overcome barriers to siRNA delivery. Int J Mol Sci. 2022;23(3):1230. doi:10.3390/ijms23031230
32. Alivernini S, Kurowska-Stolarska M, Tolusso B, Benvenuto R, Elmesmari A, Canestri S, et al. MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Ann Rheum Dis. 2020;79(1):122-131. doi:10.1136/annrheumdis-2019-215546
33. Boutet MA, Nerviani A, Pitzalis C. Role of myeloid cells in rheumatoid arthritis pathogenesis and therapeutic perspectives. Nat Rev Rheumatol. 2021;17(11):675-689. doi:10.1038/s41584-021-00666-z
34. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-0090-8
35. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in inflammatory diseases. Nat Rev Clin Oncol. 2021;18(4):234-248. doi:10.1038/s41571-020-00462-7
36. Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316-333. doi:10.1038/s41584-020-0413-2
37. Liu Y, Webb HK, Fukushima H, et al. Targeting NF-κB signaling in inflammatory diseases. Pharmacol Ther. 2022;239:108191. doi:10.1016/j.pharmthera.2022.108191
38. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway in immunity and autoimmunity. Annu Rev Med. 2021;72:11-25. doi:10.1146/annurev-med-042819-103450
39. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms and therapeutic strategies. Nat Rev Rheumatol. 2022;18(11):656-670. doi:10.1038/s41584-022-00833-0
40. Fang RH, Kroll AV, Zhang L. Nanoparticle-based manipulation of the immune system. Annu Rev Chem Biomol Eng. 2020;11:305-329. doi:10.1146/annurev-chembioeng-092319-075643
41. Li Z, Jiang H, Xu C, Gu L. A review: using nanoparticles to overcome barriers to siRNA delivery. Int J Mol Sci. 2022;23(3):1230. doi:10.3390/ijms23031230
42. Li Z, Jiang H, Xu C, Gu L. A review: using nanoparticles to overcome barriers to siRNA delivery. Int J Mol Sci. 2022;23(3):1230. doi:10.3390/ijms23031230
43. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials. Pharm Res. 2020;37:1-24. doi:10.1007/s11095-019-2728-1
44. Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2021;31(2):146-157. doi:10.1089/nat.2020.0914
45. Satapathy T, Panda PK. Evaluation of in vitro antioxidant, anti-inflammatory and anti-diabetic potential of curcumin. Indo. Am. J. Pharm. Res. 2013; 3:2808-18.
46. Satapathy T, Panda PK. Solid lipid nanoparticles: A novel carrier in drug delivery system. Research Journal of Pharmaceutical Dosage Forms and Technology. 2013 Mar 1; 5(2):1.
47. Thambi T, Park JH, Lee DS. Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives. Chem Commun. 2020;56:1416-1430. doi:10.1039/C9CC08410B
48. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-0090-8
49. Rwei AY, Lee JJ, Zhan C, Liu Q, Ok MT, Shankarappa SA, et al. Repeatable and adjustable on-demand sciatic nerve blockade with phototriggerable liposomes. Proc Natl Acad Sci USA. 2020;117(21):11367-11375. doi:10.1073/pnas.1922333117
50. Sahu K, Satapathy T, Sahu P, Chandrakar O. Molecular Biomarkers and Nano-Immunopharmacology in Inflammatory Carcinoma: Bridging Mechanisms and Therapeutic Translation. Advances in Biomarker Sciences and Technology. 2025 Dec 29. https://doi.org/10.1016/j.abst.2025.12.009
51. Kesharwani D, Paliwal R, Satapathy T, Paul SD. Rheumatiod arthritis: an updated overview of latest therapy and drug delivery. Journal of pharmacopuncture. 2019 Dec 31; 22(4):210. doi: 10.3831/KPI.2019.22.029
52. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in inflammatory diseases. Nat Rev Clin Oncol. 2021;18(4):234-248. doi:10.1038/s41571-020-00462-7
53. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2021;6:52. doi:10.1038/s41392-021-00513-4
54. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2022;18(11):656-670. doi:10.1038/s41584-022-00833-0
55. Boutet MA, Nerviani A, Pitzalis C. Metabolic regulation of macrophage activation in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(11):675-689. doi:10.1038/s41584-021-00666-z
56. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Front Immunol. 2022;13:910863. doi:10.3389/fimmu.2022.910863
57. Nygaard G, Firestein GS. Epigenetic regulation in rheumatoid arthritis synoviocytes. Nat Rev Rheumatol. 2020;16(6):316-333. doi:10.1038/s41584-020-0413-2
58. Tanaka Y. Cytokines as therapeutic targets in autoimmune diseases. Nat Rev Rheumatol. 2020;16(6):309-321. doi:10.1038/s41584-020-0419-9
59. O’Shea JJ, Gadina M, Siegel RM. Cytokines and cytokine receptors in autoimmunity: shared mechanisms and therapeutic opportunities. Nat Rev Immunol. 2022;22(1):21-36. doi:10.1038/s41577-021-00582-3
60. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2021;39:703-738. doi:10.1146/annurev-immunol-093019-125901
61. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and its therapeutic targeting in psoriasis. J Immunol. 2022;208(6):1405-1413. doi:10.4049/jimmunol.2100955
62. Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2021;22(8):970-979. doi:10.1038/s41590-021-00967-7
63. Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi:10.1038/s41590-020-0677-6
64. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2021;18(4):234-248. doi:10.1038/s41571-020-00462-7
65. Yu H, Pardoll D, Jove R. STAT3 in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2020;20(9):489-504. doi:10.1038/s41568-020-0272-6
66. Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signaling networks. Nat Immunol. 2021;22(9):1097-1108. doi:10.1038/s41590-021-00985-5
67. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2021;72:11-25. doi:10.1146/annurev-med-042819-103450
68. McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol. 2021;21(10):680-686. doi:10.1038/s41577-021-00581-4
69. Boutet MA, Nerviani A, Pitzalis C. Immunometabolism of macrophages in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(11):675-689. doi:10.1038/s41584-021-00666-z
70. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-0090-8
71. Zhang F, Wei K, Slowikowski K, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2020;21(8):928-942. doi:10.1038/s41590-020-0705-6
72. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673-694. doi:10.1038/s41573-020-0075-3
73. Walkey CD, Chan WCW. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2021;50(16):10810-10837. doi:10.1039/D1CS00335E
74. Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2023;41(1):21-31. doi:10.1038/s41587-022-01474-6
75. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2020;19(1):57-70. doi:10.1038/s41573-019-0050
76. Fu J, Dong H, Wu J, Jin Y. Emerging progress of RNA-based antitumor therapeutics. International Journal of Biological Sciences. 2023;19(10):3159-3183. doi:10.7150/ijbs.83732
77. Tenchov R, Hughes KJ, Ganesan M, Iyer KA, Ralhan K, Lotti Diaz LM, et al. Transforming medicine: cutting-edge applications of nanoscale materials in drug delivery. ACS Nano. 2025;19(12):4011-4038. doi:10.1021/acsnano.4c09566
78. Beach L, Wooley KL, Kamaly N. Regulatory framework for polymer-based nanotherapeutics in clinical translation. Journal of Controlled Release. 2026;378:112-128. doi:10.1016/j.jconrel.2025.12.004
79. Yuan X, Zhang Y, Liu C, Wang J, Zhao S. Multi-omics identification of immune-related biomarkers predicting tofacitinib response in rheumatoid arthritis. Frontiers in Immunology. 2025;16:1703209. doi:10.3389/fimmu.2025.1703209
Published
Abstract Display: 150 
PDF Downloads: 106 PDF Downloads: 39 How to Cite
Issue
Section
Copyright (c) 2026 Khemkaran Ahirwar , Shiv Kumar Bhardwaj , Abinash Satapathy , Abhisek Satapathy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.